Robert Cavaliere
Overview
Explore the profile of Robert Cavaliere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to: Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes
Liu I, Holtzman A, Rotondo R, Indelicato D, Gururangan S, Cavaliere R, et al.
J Neurooncol
. 2021 Jul;
153(3):477.
PMID: 34196917
No abstract available.
2.
Liu I, Holtzman A, Rotondo R, Indelicato D, Gururangan S, Cavaliere R, et al.
J Neurooncol
. 2021 Jun;
153(3):467-476.
PMID: 34105033
Purpose: We report disease control, survival outcomes, and treatment-related toxicity among adult medulloblastoma patients who received proton craniospinal irradiation (CSI) as part of multimodality therapy. Methods: We reviewed 20 adults...
3.
Ng A, Cavaliere R, Molchan L
Clin Podiatr Med Surg
. 2021 Mar;
38(2):245-259.
PMID: 33745655
Plantar fasciitis has been considered an acute inflammatory disorder. However, the local histologic findings represent a more chronic, degenerative state without inflammation. Patients may be stuck in a chronic state...
4.
Collier K, Valencia H, Newton H, Hade E, Sborov D, Cavaliere R, et al.
Cancer Chemother Pharmacol
. 2021 Jan;
87(5):599-611.
PMID: 33492438
Purpose: Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of...
5.
Wang J, Barth R, Cavaliere R, Puduvalli V, Giglio P, Lonser R, et al.
PLoS One
. 2020 Dec;
15(12):e0244383.
PMID: 33373402
Background: Carboplatin is a potent cytoreductive agent for a variety of solid tumors. However, when delivered systemically, clinical efficacy for the treatment of high grade gliomas is poor due to...
6.
7.
Dugan J, Haverkos B, Villagomez L, Martin L, Lustberg M, Patton J, et al.
Clin Cancer Res
. 2018 Apr;
24(14):3273-3281.
PMID: 29632007
Primary central nervous system posttransplant lymphoproliferative disorder (PCNS-PTLD) is a complication of solid organ transplantation with a poor prognosis and typically associated with Epstein-Barr virus (EBV). We hypothesized EBV lytic-phase...
8.
Wheeler L, Manzanera A, Bell S, Cavaliere R, McGregor J, Grecula J, et al.
Neuro Oncol
. 2016 Feb;
18(8):1137-45.
PMID: 26843484
Background: Despite aggressive standard of care (SOC) treatment, survival of malignant gliomas remains very poor. This Phase II, prospective, matched controlled, multicenter trial was conducted to assess the safety and...
9.
Robins H, Zhang P, Gilbert M, Chakravarti A, de Groot J, Grimm S, et al.
J Neurooncol
. 2015 Oct;
126(2):309-16.
PMID: 26508094
This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was...
10.
Mrugala M, Engelhard H, Tran D, Kew Y, Cavaliere R, Villano J, et al.
Semin Oncol
. 2014 Sep;
41 Suppl 6:S4-S13.
PMID: 25213869
Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novel...